Keros Therapeutics, Inc.
corporate_fare Company Profile
Keros Therapeutics, Inc. (NASDAQ:KROS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KROS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for KROS spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Keros Posts 70-Cent Quarterly EPS as Shares Sit Near 52-Week Low
- Keros to Receive $20M Takeda Milestone for ELRiSE MF Trial, Plans 25% Stockholder Distribution
- Keros Doses First Patient in Phase 2 DMD Trial of Rinvatercept
- Keros Therapeutics Reports Q2 Loss, Secures $20M Takeda Milestone, CFO Transition Confirmed
- Keros Therapeutics Posts Q2 2026 Loss of $1.45/Share, Extends Cash Runway into 2028, and Launches Phase 2 DMD Trial
Financial Snapshot
Short Interest & Short Volume
7.06 days to coverFINRA reported short interest of 1,086,309 shares in KROS as of the October 30, 2026 settlement, a 4.4% decrease from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 34.0% of KROS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for KROS, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.
$350M Universal Shelf Registration · $100M ATM Program Restored
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →